ADC Therapeutics (ADCT) Capital Expenditures (2023 - 2026)

ADC Therapeutics has disclosed Capital Expenditures across 4 years of filings, most recently posting $32000.0 for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $32000.0, down 87.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $32000.0 (down 94.67% YoY), and the FY2025 annual result was $264000.0, down 69.55% from the prior year.
• Capital Expenditures came in at $32000.0 for Q1 2026 at ADC Therapeutics, down from $264000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $2.6 million in Q3 2023 to a low of -$2.8 million in Q4 2023.
• The 4-year median for Capital Expenditures is $148000.0 (2025), against an average of $102333.3.
• Peak annual rise in Capital Expenditures reached 129.36% in 2024, while the deepest fall reached 119.97% in 2024.
• ADC Therapeutics' Capital Expenditures stood at -$2.8 million in 2023, then jumped by 129.36% to $829000.0 in 2024, then plunged by 68.15% to $264000.0 in 2025, then sank by 87.88% to $32000.0 in 2026.
• The last three Capital Expenditures figures came in at $32000.0 (Q1 2026), $264000.0 (Q4 2025), and -$264000.0 (Q3 2025), per Business Quant data.